



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/530,013	04/24/2000	HIROYUKI SHIMIZU	32-254P	7526

2292 7590 11/30/2001
BIRCH STEWART KOLASCH & BIRCH
PO BOX 747
FALLS CHURCH, VA 22040-0747

EXAMINER
GITOMER, RALPH J

ART UNIT	PAPER NUMBER
1623	C

DATE MAILED: 11/30/2001

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 09/530,013	Applicant(s) Shimizu et al.
Examiner Ralph Gitomer	Art Unit 1623

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on Nov 20, 2001.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-6 is/are pending in the application.
- 4a) Of the above, claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 1-6 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claims _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are objected to by the Examiner.
- 11) The proposed drawing correction filed on _____ is: a) approved b) disapproved.
- 12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

- 13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

a) All b) Some* c) None of:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

*See the attached detailed Office action for a list of the certified copies not received.

- 14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

- 15) Notice of References Cited (PTO-892) 18) Interview Summary (PTO-413) Paper No(s). _____
- 16) Notice of Draftsperson's Patent Drawing Review (PTO-948) 19) Notice of Informal Patent Application (PTO-152)
- 17) Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____ 20) Other: _____

The amendment received 11/20/01 has been entered and claims 1-6 are currently pending in this application. It is noted no references have been received with the IDS of 4/24/00.

5 The rejection under 35 USC 102(b) is hereby withdrawn in view of the claims being canceled. The amended abstract is acceptable.

10 The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

15 (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

20 This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the

examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1-6 are rejected under 35 U.S.C. 103(a) as being unpatentable over the combination of Lindberg in view of Clerico.

Lindberg (Pharmacology & Tox) entitled ~~Adsorption of Atrial Natriuretic Peptide to Different Materials~~ teaches on page 278 column 2 first paragraph, loss of recovery of ANP at different concentrations in different containers was determined where the containers include siliconized glass and coated polymers.

The claims differ from Lindberg in that they are directed to a method for inhibiting degradation of the peptides and Lindberg is directed not to storage but to contacting containers only as related to concentration.

Clerico (Clin Chem) entitled ~~Analytical Performance and Clinical Usefulness of a Commercially Available IRMA Kit for Measuring Atrial Natriuretic Peptide in Patients With Heart Failure~~ teaches on page 1631 column 2 last paragraph, storage of ANP degrades it.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to employ the containers of Lindberg which show the greatest recovery of ANP to store ANP containing specimens as shown by Clerico because Clerico teaches storing ANP in general degrades it. It would appear from Lindberg the silicone coated containers do not degrade ANP as

much as others and would therefore be desirable for storage of ANP which is known to be sensitive to degradation in storage.

5 Applicant's arguments filed 11/20/01 have been fully considered but they are not persuasive.

Applicants argue that Lindberg and Clerico do not disclose a method for inhibiting the activation of a substance degrading natriuretic peptides using specialized containers. There is no motivation to combine the references.

10 It is the examiner's position that both Lindberg and Clerico employ containers for holding ANP that are made of the same materials disclosed in the present specification. They would not use containers that would not work, and they show that the containers that they do use, do work.

15 The motivation to modify a reference can come from the knowledge of those skilled in the art, from the prior art reference itself, or from the nature of the problem to be solved. See In re Rouffet, 149 F.3d 1350, 1358, 47 USPQ2D (BNA) 1453, 1458 (Fed Cir. 1998)

20 Claims 1-6 are rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Each of the following applies in all occurrences.

25

In claim 1, ~~the~~ material inhibits the activation of a substance~~is~~ is indefinite where one would not know if they were infringing such a claim. And what the material and substance may be is not specifically claimed. Claim 6 is directed to a method for measuring by employing a container and measuring by standard means. It would appear that measuring by standard means would always employ a container and how the container is employed is not set forth.

5

The title of the invention is not aptly descriptive. A new title is required that is clearly indicative of the invention to which the claims are directed.

10

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL.** See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

15

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee

20

pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

5

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ralph Gitomer whose telephone number is (703) 308-0732. The examiner can normally be reached on Tuesday-Friday from 8:00 am - 5:00 pm.

10 The examiner can also be reached on alternate Mondays. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Geist can be reached on (703) 308-1701. The fax phone number for this Art Unit is (703) 308-4556. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose 15 telephone number is (703) 308-1234. For 24 hour access to patent application information 7 days per week, or for filing applications electronically, please visit our website at www.uspto.gov and click on the button **Patent Electronic Business Center** for more information.

20

R. Gitomer
Ralph Gitomer
Primary Examiner
Group 1623

25

RALPH GITOMER
PRIMARY EXAMINER
GROUP 1200